Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

CytoTools AG (T50) NPV

Sell:€10.00 Buy:€10.15 Change: €0.05 (0.50%)
Market closed |  Prices as at close on 7 August 2020 | Switch to live prices |
Change: €0.05 (0.50%)
Market closed |  Prices as at close on 7 August 2020 | Switch to live prices |
Change: €0.05 (0.50%)
Market closed |  Prices as at close on 7 August 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CytoTools AG is a Germany-based investment and holding company active in the biotechnology sector. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. CytoTools AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections, and pre-clinical stage CardioClean for the treatment of restenosis, diabetis and carotis-stenosis.

Contact details

Klappacher Strasse 126
+49 (6151) 9515812

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€36.80 million
Shares in issue:
3.66 million

Key personnel

  • Manfred May
    Chairman of the Supervisory Board
  • Mark-Andre Freyberg
    Chairman of the Management Board, Chief Executive Officer
  • Peter Friedl
    Deputy Chairman of the Supervisory Board
  • Dirk Kaiser
    Member of the Management Board, Chief Research Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.